Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

作者：Linda Simon, Vladan Vucinic, Kai Rejeski, Maria‐Luisa Schubert, Enver Aydilek, Eva Wagner-Drouet, O. Penack, Malte v. Bonin, Bastian von Tresckow, Marcel Teichert, Reinhard Marks, Christiane Pott, Martin Fehr, Corinna Leng, Roland Schroers, Christian Koenecke, Johannes Duell, S. Stilgenbauer, F. M. Mueller, Judith S. Hecker, Uta Brunnberg, Nicolaus Kroeger, Kai Kronfeld, Matthias Theobald, Anke Ohler, Irene M. Schmidtmann, Georg Hess, Peter Dreger · 发表于：Bone Marrow Transplantation · 年份：2026 · DOI：10.1038/s41409-025-02789-7 · 被引用次数：2 · 研究领域：Lymphoma Diagnosis and Treatment、CAR-T cell therapy research、T-cell and Retrovirus Studies

Mantle Cell Lymphoma (MCL) is an incurable B-cell neoplasm, representing 6–8% of newly diagnosed B-cell lymphomas [ 1 ]. Brexucabtagene-autoleucel (brexu-cel, Tecartus®) is a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy approved in Europe for treatment of relapsed/refractory (r/r) MCL after two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi) [ 2 ]. Approval was based on a small population of 68 patients in the ZUMA-2 trial [ 2 ]. Therefore, data on toxicities and long-term outcomes in a real-world setting are of great value to confirm the potential and show limitations of brexu-cel.